Avadel Pharmaceuticals PLC (AVDL) Q3 2024 Earnings Call Highlights: Strong Patient Growth and ... [Yahoo! Finance]
Avadel Pharmaceuticals plc - Ordinary Share (AVDL)
Last avadel pharmaceuticals plc - ordinary share earnings: 3/12 07:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
avadel.com
Company Research
Source: Yahoo! Finance
Operating Expenses: $44.2 million GAAP operating expenses, with $37.8 million in cash operating expenses. Adjusted EBITDA: Positive $6.1 million. Cash and Equivalents: $66 million as of September 30. Active Patients: 2,300 patients on therapy as of September 30. New Patient Starts: 700 patients initiated therapy in Q3. Gross Margin: Impacted by approximately 3.5% due to a onetime adjustment related to potential royalty. Warning! GuruFocus has detected 5 Warning Signs with AVDL. Release Date: November 12, 2024 For the complete transcript of the earnings call, please refer to the full earnings call transcript Avadel Pharmaceuticals PLC ( NASDAQ:AVDL ) reported consistent patient growth for LUMRYZ, with 2,300 active patients and 700 new initiations in Q3, resulting in $50 million in net revenue. The company received FDA approval and orphan drug exclusivity for LUMRYZ in pediatric patients, expanding its treatment reach. LUMRYZ is showing strong uptake among new to
Show less
Read more
Impact Snapshot
Event Time:
AVDL
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
AVDL alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
AVDL alerts
High impacting Avadel Pharmaceuticals plc - Ordinary Share news events
Weekly update
A roundup of the hottest topics
AVDL
News
- State-of-the-science webinar will explore narcolepsy and hypersomniaPR Web
- Avadel Pharmaceuticals plc (NASDAQ: AVDL) had its price target lowered by analysts at HC Wainwright from $27.00 to $25.00. They now have a "buy" rating on the stock.MarketBeat
- Avadel Pharmaceuticals to Present at the Jefferies London Healthcare ConferenceGlobeNewswire
- Avadel Pharmaceuticals plc (AVDL) Q3 2024 Earnings Call Transcript [Seeking Alpha]Seeking Alpha
- Avadel Pharmaceuticals plc (NASDAQ: AVDL) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $22.00 price target on the stock.MarketBeat
AVDL
Earnings
- 11/12/24 - Beat
AVDL
Sec Filings
- 11/14/24 - Form SC
- 11/14/24 - Form SC
- 11/13/24 - Form SC
- AVDL's page on the SEC website